Janus kinases inhibitors for treating patients with rhupus.
Sign Up to like & getrecommendations! Published in 2020 at "Joint bone spine"
DOI: 10.1016/j.jbspin.2020.05.010
Abstract: HIGHLIGHTS • baricitinib and tofacitinib are effective in patients with Rhupus • JAK inhibitors are an alternative option in patients with refractory SLE • JAK inhibitors have a steroid-sparing effect in patients with Rhupus read more here.
Keywords: inhibitors treating; patients rhupus; kinases inhibitors; treating patients ... See more keywords
Abstract P5-05-14: Cyclin-dependent kinases inhibitors improve antimetabolite drug potency depending on SAMHD1 expression
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Research"
DOI: 10.1158/1538-7445.sabcs19-p5-05-14
Abstract: Introduction Cyclin-dependent kinase (CDK) 4/6 inhibitors represent a new paradigm in the treatment of hormone receptor (HR) positive and HER-2 negative metastatic breast cancer (MBC). However, despite their evident clinical benefit, the cellular and molecular… read more here.
Keywords: cyclin dependent; dependent kinases; drug; cyclin ... See more keywords
Cyclin-dependent kinases 4 and 6 inhibitors in HR+/HER2- advanced breast cancer.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.e13048
Abstract: e13048Background: In a previous meta-analysis which published in 23rd NCCN Annual Conference, we reported that the addition of cyclin-dependent kinases 4 and 6 inhibitors (CDKi) to endocrine therapy (ET) improved progression-free survival (PFS) for patients… read more here.
Keywords: dependent kinases; cyclin dependent; breast cancer; advanced breast ... See more keywords
Design of Sphingosine Kinases Inhibitors: Challenges and Recent Developments.
Sign Up to like & getrecommendations! Published in 2019 at "Current pharmaceutical design"
DOI: 10.2174/1381612825666190404115424
Abstract: BACKGROUND Sphingosine kinases (SphKs) catalyze the phosphorylation of sphingosine to form the bioactive sphingolipid metabolite sphingosine-1-phosphate (S1P). S1P is an important lipid mediator with a wide range of biological functions; it is also involved in… read more here.
Keywords: sphk1 sphk2; design sphingosine; inhibitors challenges; sphingosine ... See more keywords
2-[18F]FDG PET in the Management of Radioiodine Refractory Differentiated Thyroid Cancer in the Era of Thyrosin-Kinases Inhibitors: A Real-Life Retrospective Study
Sign Up to like & getrecommendations! Published in 2022 at "Diagnostics"
DOI: 10.3390/diagnostics12020506
Abstract: Purpose To evaluate the role of 2-[18F]FDGPET/CT in the follow-up of radioiodine refractory thyroid cancer (RR-TC). Methods Forty-six 2-[18F]FDGPET/CT scans from 14 RR-TC patients were considered. Thyroid function tests: thyroglobulin (Tg), levothyroxine (LT4), and tyrosine-kinases… read more here.
Keywords: 18f fdgpet; thyroid cancer; radioiodine refractory; kinases inhibitors ... See more keywords
In Silico and In Vitro Study of Janus Kinases Inhibitors from Naphthoquinones
Sign Up to like & getrecommendations! Published in 2023 at "Molecules"
DOI: 10.3390/molecules28020597
Abstract: Janus kinases (JAKs) are involved in numerous cellular signaling processes related to immune cell functions. JAK2 and JAK3 are associated with the pathogenesis of leukemia and common lymphoid-derived illnesses. JAK2/3 inhibitors could reduce the risk… read more here.
Keywords: silico vitro; study janus; kinases inhibitors; janus kinases ... See more keywords